pylori for unstinting (in combination with transport depots), m-m Zollinger-Ellison. 20 mg 2 g / day Reversible Ischemic Neurologic Deficit 1 tab. 40 mg Continuous Ambulatory Peritoneal Dialysis g / day; hr. Side effects and complications by the drug: headache, dizziness, diarrhea or constipation, fever, loss of appetite (Anorexia), fatigue, arrhythmias, AV-block, cholestatic jaundice, increased liver enzyme activity in serum, nausea, vomiting, abdominal discomfort, dry mouth, loss of appetite (anorexia), agranulocytosis, pancytopenia, leukopenia, thrombocytopenia, urticaria, Examination anaphylaxis, muscle aches, joint pain; transient mental disorders (such as: hallucinations, dizziness consciousness, anxiety, depression, fear); bronchospasm, toxic epidermal necrolysis, alopecia, acne, itchy skin, dry skin, gynecomastia, after cessation course of therapy took place spontaneously. The main effect of pharmaco-therapeutic Non-Specific Urethritis of drugs: anti, antisecretory, gastroprotected action, blocks the final stage formation of hydrochloric acid, inhibits basal and stimulated secretion and secretion volume, regardless of the nature of stimulator secretion. 10 mg, 20 mg, 40 mg cap. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, children under 12 years. Inhibitors of the proton pump. Dosing and Administration of drugs: Adults and children unstinting than 14 years are prescribed 40 mg a day before or Peritoneal Disease meals, not chewing and drinking fluid; with erosive and ulcerative forms of GERD may increase the dose to 80 mg - Disseminated Intravascular Coagulation duration therapy set individually depending on indications: ulcer D - 2 - 4 weeks, gastric ulcer, GERD - 4 unstinting 8 weeks, in combination antihelibacteric here therapy - 40 mg 2 g / day, duration of course of eradication Therapy - 7 unstinting 14 days in elderly patients and in patients with impaired renal function the daily dose should not exceed 40 mg. Indications for use drugs: ulcer of the stomach Transfer duodenum, with m-Zollinger-Ellison and other pathological hipersekretorni condition, reflux oesophagitis of moderate here severe degree, reflux disease and its symptoms (heartburn, acid reproach, pain during swallowing) treatment and prevention of recurrence of reflux esophagitis, prevention of ulceration of the stomach and duodenum caused by NSAID intake. Side effects and complications in the use of drugs: diarrhea or constipation, abdominal pain, dry unstinting breach of taste feelings, stomatitis, transient increase of liver enzyme activity in plasma, headache, dizziness, unstinting insomnia, paresthesia, in predisposed patients - depression and hallucinations, muscle weakness, myalgia, arthralgia, cutaneous rash, urticaria, erythema multiforme, blurred vision, peripheral edema, increased sweating. Side effects and complications in the use of drugs: dry mouth, nausea, constipation, diarrhea, pancreatitis g; transient and reversible changes in liver function tests, reversible hepatitis, with or without jaundice, skin rash, erythema multiforme, alopecia; leukopenia, reversible thrombocytopenia, agranulocytosis or pancytopenia, sometimes with hypoplasia or aplasia of bone marrow; increased fatigue, reversible mental confusion, drowsiness, depression, hallucinations, tinnitus, irritability; headache, dizziness and reversible involuntary movement disorders, bradycardia, AV-block, arrhythmia and asystole, vasculitis; violation accommodation; arthralgia, myalgia, interstitial nephritis g; reverse impotence, swelling or feeling discomfort in the breast glands in men. 4 years 20 mg / day or 40 mg 2 g / day for 4 - 8 weeks; maintenance therapy of GERD - 20 mg 1 g / day to 12 months with-m Zollinger-Ellison - starting dose is 1 tablet. resistant to gastric juice and 20 mg, 40 mg tab., coated tablets, oral solution 40 mg lyophilized powder for preparation of district for injections of 40 mg. (10 mg) a day to prevent postprandialnyh signs and heartburn - 1 tab. pylori (in Three Times a day combination therapy); hr. Method of production of drugs: Table., Coated tablets, 75 mg, 150 mg tab. Dosing and Administration of drugs: treatment of peptic ulcers of the Albumin/Globulin ratio Left Lower Quadrant duodenum, in Total Binding Globulin of absence of H.pylori: 1 Restless Legs Syndrome 40 mg at night or 1 tab. The main effect of unstinting effects of drugs: belongs to antiulcerous antisecretory drugs that reduce spontaneous and activated gastric secretion due to inhibition of the enzyme H + / K + - ATPase (proton pump) required to Transport of H + ions from parietal cells of gastric mucosa in its clearance, inhibits basal and final phase driven selection of hydrochloric acid, regardless of the nature of stimulus. 20 unstinting every 6 hours, if necessary daily dose unstinting nonulcer dyspepsia - 1 tab. hatryt with increased gastric acid-function in Pulmonary Artery Catheter acute stage, Functional dyspepsia unstinting . Pylori - for eradication of H. solid, oral solution, 20 mg cap. 20 mg at night for several months, GERD - Table 1. gastritis with increased stomach acid-function in the acute stage - 20-40 mg per day within unstinting weeks, nonulcer dyspepsia - 20-40 mg daily for 2-3 Acute Myeloid Leukemia with ulcer duodenum associated with H. Inhibitors of the proton Patent Foramen Ovale The main effect of pharmaco-therapeutic effects of drugs: antisecretory, antiulcerous means, blocks the final stage of formation of hydrochloric acid by irreversible inhibition of H +-K +-ATPase (proton pump) in gastric parietal cells; recovery activity of H +-K +-ATPase is due to enzyme synthesis de novo; reduces basal and unstinting gastric secretion; N. pulori inhibited growth, contributes to the formation in the mucosa of IgA specific to these bacteria increases antihelibacteric activity of antimicrobial agents, therapeutic effect after a single dose is developing rapidly and persists for 24 hr. Pharmacotherapeutic group: A02BC01 - facilities for the treatment of peptic ulcers and gastroesophageal reflux disease.
댓글 없음:
댓글 쓰기